Navigation Links
Abbott Completes Visiogen Acquisition
Date:10/20/2009

ABBOTT PARK, Ill., Oct. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that it has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.

Visiogen's Synchrony® accommodating IOL is a significant advancement in artificial lens technology. It is designed to mimic the eye's natural ability to change focus (accommodation), delivering improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity.

Abbott's $400 million cash purchase of Visiogen boosts the company's presence in the vision care segment, which it entered in February 2009 with its acquisition of Advanced Medical Optics. Abbott Medical Optics offers a range of cataract, refractive and corneal products designed to meet the needs of patients who suffer from a wide range of vision disorders and seek greater freedom from the limitations of eyeglasses.

"Visiogen immediately provides Abbott Medical Optics with a talented team of dedicated professionals and an entry point into the accommodating IOL market," said Jim Mazzo, senior vice president, Abbott Medical Optics. "The innovative Synchrony accommodating IOL expands our diverse portfolio of cataract treatments and allows Abbott the opportunity to help the more than 1 billion people worldwide suffering from presbyopia."

Synchrony has received CE mark designation and has been available commercially in Europe since January 2009. It also is currently under review by the U.S. Food and Drug Administration (FDA).

Intraocular lenses are implanted in a patient's eye after the removal of the natural lens that has become clouded by a cataract. Conventional monofocal IOLs are designed to focus primarily at a distance and not to correct presbyopia, an age-related change in vision in which the eye's lens can no longer adjust its focal length to allow clear vision at different distances.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

SOURCE Abbott


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... Israel , May 30, 2017 DarioHealth Corp. (NASDAQ: ... big data solutions, today announced that it will be presenting at ... at 8:00 AM PT. Erez Raphael , CEO, of DarioHealth ... The conference will be held on June 6th & 7th, 2017 ... companies in the small / micro-cap space. ...
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... ... KICKICO , a protocol built on Ethereum for more transparent ICO and ... funding campaigns. KICKICO developers are testing the platform, which will launch for the public ... through the power of many - has been around for about ten years as ...
(Date:6/25/2017)... ... ... a feel-good lyric music video in Final Cut Pro X with ProLyric from Pixel Film ... the lyrics to any song. ProLyric flies in the text for each section and it ... added modularly for optimal control. ProLyric makes editing any music video or text-based production easier ...
(Date:6/25/2017)... ... 25, 2017 , ... CareSet Labs released the Root NPI Graph today at ... new, greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. ... subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as ...
(Date:6/24/2017)... ... 24, 2017 , ... Genes Advice, a new company based ... and Texas doctors' offices and clinics. This breakthrough testing is part of the ... the role genes play in determining an individual's tolerance of and reaction to ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up ... Home and business owners should be aware that the summer months provide more than ... mechanical locks and keys can be negatively affected from direct exposure to the sun. ...
Breaking Medicine News(10 mins):